Article Details

CRISPR biotech Caribou Biosciences' IPO reels in $304M for next-gen cell therapy

Retrieved on: 2021-07-23 18:22:30

Tags for this article:

Click the tags to see associated articles and topics

CRISPR biotech Caribou Biosciences' IPO reels in $304M for next-gen cell therapy. View article details on hiswai:

Excerpt

The biologic drug candidates that Absci develops stem from a technology ... describes as a marriage of artificial intelligence and synthetic biology.

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up